|
FOLFOX4/XELOX in stage II–III colon cancer: Efficacy results of the Italian three or six colon adjuvant (TOSCA) trial. |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Amgen; Bayer |
Speakers' Bureau - Lilly; Roche |
Research Funding - Sanofi |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Travel, Accommodations, Expenses - Celgene; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bayer; Italfarmaco; Lilly; Sirtex Medical |
Travel, Accommodations, Expenses - ArQule |
Other Relationship - Amgen |
|
|
Travel, Accommodations, Expenses - Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Travel, Accommodations, Expenses - Merck |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |